ArticleThe Kaohsiung journal of medical sciences2019
Rhein lysinate improves motor function in rats with spinal cord injury via inhibiting p38 MAPK pathway.
Article in The Kaohsiung journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Editorial: Plant and fungal extracts and metabolites in neurotherapy: exploring their pharmacology and potential clinical uses.Frontiers in pharmacology · 2025Article
- Molecular dynamic simulation reveals the inhibiting impact of Rhein on wild-type and P29S-mutated Rac1.Frontiers in molecular biosciences · 2024Article
- ROS generation and p-38 activation contribute to montmorillonite-induced corneal toxicity in vitro and in vivo.Particle and fibre toxicology · 2023Article
- Rhein ameliorates transverse aortic constriction-induced cardiac hypertrophyFrontiers in pharmacology · 2022Article
- Rhein lysinate improves motor function in rats with spinal cord injury via inhibiting p38 MAPK pathway.The Kaohsiung journal of medical sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The current study aims to investigate the effect of rhein lysinate (RHL) on neuromotor function in rats with spinal cord injury (SCI) and to explore the underlying mechanism. A total of 63 adult male SD rats were randomly divided into the sham group, SCI group and RHL group (SCI-RHL group), with 21 rats in each group. Basso Beattie Bresnahan (BBB) scoring and the inclined plate test were used to evaluate the changes in motor function after SCI. Then, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and malondialdehyde (MDA) contents were quantified. Caspase-3-positive cells in spinal cord tissue were detected by immunohistochemical (IHC) staining, and protein expression was detected by Western blots. Here, our data showed that compared with the SCI group, the BBB score and inclined plate test score of the SCI-RHL group were significantly higher than those of the SCI group 7 days after the RHL intervention. After 7 days of RHL treatment, the activities of SOD and GSH-Px in the spinal cord increased significantly. At the same time, RHL reduced the MDA content in spinal cord tissue of SCI rats. Moreover, cleaved-caspase-3-positive cells and apoptotic cells were significantly lower in the SCI-RHL group than in the SCI group. More importantly, p38 mitogen-activated protein kinase (p38 MAPK) was significantly decreased in the SCI-RHL group compared with the SCI group. In summary, RHL can inhibit the activation of the p38 MAPK pathway after SCI, thereby reducing the apoptosis of spinal cord neurons and improving the neuromotor function of SCI rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.